Back to top

EyePoint assumed with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald assumed coverage of EyePoint (EYPT) with an Overweight rating and $47 price target ahead of Phase 3 data in neovascular AMD. The ...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

EyePoint, Inc. (EYPT)